Vir Biotechnology (VIR) Total Non-Current Liabilities (2018 - 2026)

Vir Biotechnology has reported Total Non-Current Liabilities for 9 years, with the latest figure at $193.4 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 22.36% year-over-year to $193.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $193.4 million (down 22.36% YoY) and the FY2025 annual result came in at $216.0 million, down 7.65% from the prior year.
• Total Non-Current Liabilities fell to $193.4 million in Q1 2026 per VIR's latest filing, from $216.0 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $867.2 million in Q1 2022 and troughed at $193.4 million in Q1 2026.
• A 5-year average of $385.0 million and a median of $249.1 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities soared 101.81% in 2022, then slumped 66.17% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $699.2 million in 2022, then sank by 56.68% to $302.9 million in 2023, then retreated by 22.79% to $233.9 million in 2024, then declined by 7.65% to $216.0 million in 2025, then fell by 10.45% to $193.4 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $193.4 million, $216.0 million, and $210.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.